Latest News for PHGUF
Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA.
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PHGUF.
Senate Trading
No Senate trades found for PHGUF.
U.S. House Trading
No House trades found for PHGUF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.